JNJ

186.02

-0.73%↓

ABT

125.16

-1.27%↓

ISRG

539.84

-0.58%↓

DHR

218.01

-0.1%↓

BSX

100.44

-0.86%↓

JNJ

186.02

-0.73%↓

ABT

125.16

-1.27%↓

ISRG

539.84

-0.58%↓

DHR

218.01

-0.1%↓

BSX

100.44

-0.86%↓

JNJ

186.02

-0.73%↓

ABT

125.16

-1.27%↓

ISRG

539.84

-0.58%↓

DHR

218.01

-0.1%↓

BSX

100.44

-0.86%↓

JNJ

186.02

-0.73%↓

ABT

125.16

-1.27%↓

ISRG

539.84

-0.58%↓

DHR

218.01

-0.1%↓

BSX

100.44

-0.86%↓

JNJ

186.02

-0.73%↓

ABT

125.16

-1.27%↓

ISRG

539.84

-0.58%↓

DHR

218.01

-0.1%↓

BSX

100.44

-0.86%↓

Search

Eli Lilly and Co.

Open

SectorHealthcare

827.52 1.04

Overview

Share price change

24h

Current

Min

814

Max

827.25

Key metrics

By Trading Economics

Income

2.9B

5.7B

Sales

2.8B

16B

P/E

Sector Avg

54.049

37.003

EPS

6.31

Dividend yield

0.68

Profit margin

36.384

Employees

47,000

EBITDA

3.3B

7.5B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+10.89% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.68%

2.25%

Next Earnings

30 Oct 2025

Next Dividend date

10 Dec 2025

Next Ex Dividend date

14 Nov 2025

Market Stats

By TradingEconomics

Market Cap

50B

741B

Previous open

826.48

Previous close

827.52

News Sentiment

By Acuity

48%

52%

153 / 373 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Eli Lilly and Co. Chart

Past performance is not a reliable indicator of future results.

Related News

24 Oct 2025, 13:04 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Agrees to Acquire Adverum Biotechnologies

23 Sept 2025, 03:10 UTC

Acquisitions, Mergers, Takeovers

South Korea's Celltrion Plans to Invest $1 Billion to Acquire, Expand U.S. Facility

25 Aug 2025, 15:59 UTC

Major Market Movers

Immuneering Shares Climb On Supply Agreement with Eli Lilly

24 Oct 2025, 12:34 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Says Transaction Is Expected to Close in the 4Q >LLY

24 Oct 2025, 12:34 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly: Offer Also Includes 1 Non-Transferrable Contingent Value Right Entitling Holder to Receive Up to an Additional $8.91 Per CVR in Cash Upon the Achievement of 2 Milestones, for Total Potential Consideration of Up to $12.47/Shr >LLY

24 Oct 2025, 12:33 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Launch Tender Offer to Acquire All Outstanding Shares of Adverum for $3.56/Shr >LLY

24 Oct 2025, 12:30 UTC

Acquisitions, Mergers, Takeovers

Lilly To Acquire Adverum Biotechnologies >LLY ADVM

17 Oct 2025, 15:56 UTC

Earnings

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 Oct 2025, 13:53 UTC

Earnings

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 Oct 2025, 13:04 UTC

Earnings

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, Interactive Brokers, CSX, and More -- Barrons.com

17 Oct 2025, 11:19 UTC

Earnings

These Stocks Are Moving the Most Today: Zions Bancorp, Amex, Oracle, Novo Nordisk, Lilly, Interactive Brokers, CSX, AST SpaceMobile, and More -- Barrons.com

17 Oct 2025, 10:50 UTC

Earnings

These Stocks Are Moving the Most Today: Zions Bancorp, Oracle, Novo Nordisk, Lilly, Interactive Brokers, CSX, AST SpaceMobile, Amex, and More -- Barrons.com

26 Sept 2025, 13:55 UTC

Earnings

These Stocks Are Moving the Most Today: Eli Lilly, Intel, Paccar, GlobalFoundries, Boeing, Concentrix, Costco, and More -- Barrons.com

26 Sept 2025, 09:41 UTC

Earnings

These Stocks Are Moving the Most Today: Eli Lilly, Wayfair, Intel, Oracle, Concentrix, Costco, and More -- Barrons.com

23 Sept 2025, 02:55 UTC

Acquisitions, Mergers, Takeovers

South Korea's Celltrion Plans to Invest $1B to Acquire, Expand U.S. Facility

23 Sept 2025, 01:27 UTC

Acquisitions, Mergers, Takeovers

Celltrion: Investment Aims to Remove U.S. Tariff Risks

23 Sept 2025, 01:26 UTC

Acquisitions, Mergers, Takeovers

Celltrion: To Invest Extra KRW700B to Expand Facility in Branchburg, New Jersey

23 Sept 2025, 01:26 UTC

Acquisitions, Mergers, Takeovers

Celltrion: To Spend KRW700B for Acquisition, Initial Operating Costs

23 Sept 2025, 01:25 UTC

Acquisitions, Mergers, Takeovers

Celltrion to Buy Biologics Facility in U.S. for $330M From Eli Lilly

22 Sept 2025, 13:43 UTC

Acquisitions, Mergers, Takeovers

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

26 Aug 2025, 13:57 UTC

Earnings

These Stocks Are Moving the Most Today: EchoStar, AT&T, AMD, Lilly, DJT, Talen Energy, Semtech, and More -- Barrons.com

26 Aug 2025, 11:37 UTC

Earnings

These Stocks Are Moving the Most Today: AT&T, EchoStar, AMD, Lilly, Interactive Brokers, Talen Energy, and More -- Barrons.com

12 Aug 2025, 22:15 UTC

Acquisitions, Mergers, Takeovers

Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data -- Barrons.com

8 Aug 2025, 19:34 UTC

Market Talk

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8 Aug 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 Aug 2025, 16:20 UTC

Earnings

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 4th Update

7 Aug 2025, 14:18 UTC

Market Talk
Earnings

Eli Lilly's Orforglipron Results Weigh on Stock -- Market Talk

7 Aug 2025, 13:54 UTC

Earnings

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 3rd Update

7 Aug 2025, 12:12 UTC

Earnings

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 2nd Update

7 Aug 2025, 11:58 UTC

Earnings

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- Update

Peer Comparison

Price change

Eli Lilly and Co. Forecast

Price Target

By TipRanks

10.89% upside

12 Months Forecast

Average 909.44 USD  10.89%

High 1,190 USD

Low 700 USD

Based on 22 Wall Street analysts offering 12 month price targets forEli Lilly and Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

22 ratings

18

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

N/A / 884.54Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

153 / 373 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
help-icon Live chat